OR5A1

Across TCGA pan-cancer cohorts, OR5A1 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR5A1 data layer compared with 15 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher OR5A1 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR5A1 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

OV, HNSC, and SKCM are the cancer types where OR5A1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	OS	Median	III,IV	0.084	0.837	<.001	12	view →
HNSC	DFS	Median	II,III,IV	0.170	0.662	.016	9	view →
SKCM	DFS	Median	IV	0.036	0.433	<.001	9	view →
SARC	DFS	Median	All	0.095	0.632	.002	6	view →
BLCA	OS	Median	II,III,IV	1.000	0.413	.043	4	view →
STAD	DFS	Median	All	0.211	0.709	.015	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR5A1–OV (OS)

Open the OV breakdown →